ATNF

180 Life Sciences Corp. [ATNF] Stock Forecast

Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000

ATNF Stock Summary

Top 10 Correlated ETFs

ATNF

Top 10 Correlated Stocks

ATNF

In the News

ATNF Financial details

Company Rating
-
Market Cap
1.84M
Income
-19.9M
Revenue
0
Book val./share
-
Cash/share
-
Dividend
-
Dividend %
-
Employees
4
Optionable
No
Shortable
Yes
Earnings
13 May 2024
P/E
-0.04
Forward P/E
-
PEG
0
P/S
-
P/B
-11.7
P/C
-
P/FCF
-0.19
Quick Ratio
0.58
Current Ratio
0.7
Debt / Equity
-
LT Debt / Equity
-
-
-
EPS (TTM)
-64.18
EPS next Y
-
EPS next Q
-
EPS this Y
-86.42%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
-
Revenue last 5Y
-
Revenue Q/Q
-
EPS Q/Q
-90.66%
-
-
-
-
SMA20
-14.19%
SMA50
-39.82%
SMA100
-29.26%
Inst Own
-
Inst Trans
-
ROA
-815%
ROE
-645%
ROC
-116.8%
Gross Margin
-
Oper. Margin
-
Profit Margin
-
Payout
-
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
1.805-27.93
52W High
-95.37%
52W Low
+25%
RSI
33.17
Rel Volume
0.27
Avg Volume
93.39K
Volume
25.39K
Perf Week
-8.76%
Perf Month
-24.7%
Perf Quarter
-35.57%
Perf Half Y
-34.55%
-
-
-
-
Beta
0.437
-
-
Volatility
0.04%, 0.1%
Prev Close
-2.34%
Price
1.25
Change
-2.34%

Something similar

Top by Market Cap
LLY.SW
BRK-A
AVGO
NVD.DE
MIX.JO
Top Correlated ETFs
PSCE
YANG
FXP
GLL
LITP
Top Correlated Stocks
CHEK
SCVL
FCONSUMER.NS
CAL
CTXR
Similar Market Cap
GRDAF
CWBR
XDNA
ARON.SW
WTDR.DE

Company Profile

Healthcare Biotechnology
  • Volume Average 93.39K
  • Market Capitalization 1.84M
  • Employee 4
  • CEO Dr. James N. Woody M.D., Ph.D.
  • Headquarters Palo Alto,CA,US
  • IPO Date 2017-06-27
  • Website https://180lifesciences.com

1180 Life Sciences Corp., a clinical-stage biotechnology company, develops therapeutics for unmet medical needs in chronic pain, inflammation, fibrosis, and other inflammatory diseases. Its product development platforms include fibrosis and anti-tumor necrosis factor (anti-TNF) platform, which is under Phase IIb clinical trials that focuses on fibrosis and Anti-TNF; Synthetic Cannabidiol (CBD) Analogs platform, which is under preclinical trials that are man-made derivatives of CBD; and a7nAChR platform, an immune suppressive, which is under preclinical trails that focuses on alpha 7 nicotinic acetylcholine receptor. The company was incorporated in 2016 and is headquartered in Palo Alto, California.